<DOC>
	<DOCNO>NCT02811120</DOCNO>
	<brief_summary>A previous cohort 93 clinical trial participant receive quadrivalent meningococcal conjugate vaccine , include strain ACW Y , teenage year . The vaccine also contain component diphtheria tetanus link meningitis component , process call conjugation , improve effectiveness . Participants age 19-25 invited take part study , ass antibody persistence time . This provide information duration protection relate current antibody level measure previous study , underpin national immunisation schedule provide optimal immunisation schedule . As well meningitis antibody investigator assess diphtheria tetanus antibody level . The study involve single blood test 8mL . Participants informed result antibody level infer protection strain W offer extra dose vaccine part duty care . The study involve single blood test 8mL . Participants informed result antibody level infer protection strain W offer extra dose vaccine .</brief_summary>
	<brief_title>PRIME Follow - Quadri Meningo Vacinees</brief_title>
	<detailed_description>The UK first country world introduce meningococcal serogroup C conjugate vaccine ( MCC ) routine immunisation schedule 1999 . This effectively reduce incidence disease , high young 1 year routine use infant immunisation schedule , age around 15-17 year catch campaign . Subsequently , meningococcal vaccination schedule undergone several revision , include : - 2006 - reduction number dos give infant manufacturer advise three JCVI instruct two combination MCC dose second year life Hib vaccine , form Menitorix - 2013 - reduction single dose infancy introduction booster teenage year due study demonstrate antibody persistence short live childhood - 2015 - amendment teenage booster dose MCC quadrivalent meningococcal conjugate vaccine address increase incidence serogroup W disease age group ( PHE website - Meningococcal data ) , introduction Bexsero infant schedule ostensibly address meningococcal B disease potential cross protection serogroups , currently assess another NVEC study . - 2016 - removal MCC 3 month age . Given previous demonstration poor antibody persistence MenC antibodies two year follow 2006 schedule , 43 % , 22 % 23 % child achieve SBA titre ≥8 two year follow booster dose Menitorix™ prim NeisVac-C™ , Menjugate™ Meningitec™ , respectively , concern protection afford quadrivalent vaccine administer around 14 year age , whether provide protection young adulthood risk disease high . In previous study group ( Eudract number 2010-022505-18 ) , adolescent age 16-19 year randomise receive one two license meningococcal ACWY conjugate vaccine : 1 . Menveo™ ( GSK ) This vaccine contain bacterial capsular oligosaccharide serogroups A , C , W , Y conjugate protein carrier , CRM197 , nontoxigenic natural variant diphtheria toxin . The MenACWY vaccine test several age group show generally well tolerate immunogenic . Menveo™ indicate use 2 year age risk . 2 . Nimenrix ( Pfizer ) This vaccine contain bacterial capsular oligosaccharide serogroups A , C , W , Y conjugate Tetanus Toxoid ( TT ) . This MenACWY-TT vaccine test several age group show safe immunogenic . It indicate use 12 month age risk . The cohort include study one first receive meningococcal C conjugate vaccine young child , subsequently booster form meningococcal quadrivalent ( ACWY ) conjugate vaccination age 16-19 year . This group 93 young adult , age 20-24 year , provide unique opportunity study persistence meningococcal serogroup-specific antibody time . This particularly important give recent increase incidence meningococcal W disease prompt amendment national schedule include booster meningococcal quadrivalent vaccine teenage year .</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Individual willing able give write informed consent participation . Individual originally enrol randomised parallel group study quadrivalent meningococcal vaccination . Known bleed diathesis ( condition may associate prolonged bleeding time ) . Any significant condition circumstance , opinion investigator , may either put participant risk participation study , may influence result study , participant 's ability participate study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>meningococcal</keyword>
	<keyword>conjugate</keyword>
	<keyword>vaccine</keyword>
	<keyword>quadrivalent</keyword>
	<keyword>meningococcal quadrivalent conjugate vaccine</keyword>
</DOC>